Navigation Links
2 Drugs Fail to Prevent Diabetes in the Overweight
Date:3/14/2010

Diovan, Starlix also had limited or no effect in shielding users from cardiovascular woes, study finds

SUNDAY, March 14 (HealthDay News) -- Hopes that two available drugs could help prevent diabetes and the problems it causes in overweight people with poor sugar metabolism have been dashed by a major international study.

The trial involved two drugs prescribed for other reasons -- Diovan (valsartan), a blood pressure medication; and Starlix (nateglinide), which is given to control existing type 2 diabetes.

The study was financed by Novartis, the drug company that markets both products.

The Starlix portion of the five-year trial, involving more than 9,300 overweight adults, found the drug had no benefit in reducing the incidence of newly diagnosed diabetes, cardiovascular death or events such as heart attack, stroke and heart failure.

The Diovan portion did find a modest effect -- 14 percent -- in preventing new diabetes cases. However, as was the case in the Starlix part of the trial, using Diovan led to no reduction in the cardiovascular conditions for which diabetes is a major risk factor.

Results of the trial were reported in two papers released early on March 13 by the New England Journal of Medicine, and slated for presentation Sunday at the American College of Cardiology's annual meeting, in Atlanta.

"It would be great if we had something that would prevent diabetes and cardiovascular disease at the same time," said Dr. Robert M. Califf, vice chancellor for clinical research at Duke University, and one of the leaders of the trial. "We didn't get that."

And despite the faintly positive results of the Diovan portion of the trial, "in neither case would we recommend such prophylactive [preventive] treatment in people who don't have diabetes but have abnormal glucose tolerance," Califf said.

So, lifestyle remains the key factor in preventing obesity and p
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Long-Term Use of Osteoporosis Drugs Linked to Fractures
2. Find Safe, Affordable Prescription Alternatives at SplitMed.com - New Site for Discount Prescription Drugs
3. UW Symposium: How Disease, Therapy, Drugs and Meditation Reshape the Brain
4. PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest
5. Quantity vs. quality: Long-term use of bone-building osteoporosis drugs
6. Physician calls for more rigorous standards for drugs up for FDA approval
7. The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years
8. Bleeding Alert Sounded for Stroke Drugs
9. Certain Bone Drugs May Lower Breast Cancer Risk
10. New Drugs, Approaches Offer Hope Against Prostate Cancer
11. Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Atlanta, Georgia (PRWEB) May 04, 2015 Each ... the country to raise funds and awareness for breast cancer. ... Plastic Surgery will be featured as the entertainment sponsor for ... the Cure” on May 9 at the Lenox Square Mall. ... year’s Atlanta race, and to raise $1.2 million. Perimeter Plastic ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be ... Group (RUG) Conference in Baltimore, MD from May 11 ... Group provides an opportunity for clients to gather to ... , In addition to sponsoring the event, TROY Healthcare ... RUG Conference. Attendees can stop by the TROY booth ...
(Date:5/4/2015)... May 04, 2015 In May of 2010, ... his own life. In the wake of this tragedy, Ty’s ... an organization that exposes the grim reality of bullying and ... platform for Kirk and Laura to share their story and ... from happening to another family — a mission that took ...
(Date:5/4/2015)... 04, 2015 EY today announced that ... a finalist for the EY Entrepreneur Of The Year® ... awards program recognizes entrepreneurs who demonstrate excellence and extraordinary ... personal commitment to their businesses and communities. Mr. ... of independent judges. Award winners will be announced ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 New findings ... Brain Tumor Association (ABTA) show that people diagnosed with ... and treatment options, including clinical trials, at the time ... to make difficult decisions about their course of treatment. ... of the first nationwide brain tumor volunteer network, the ...
Breaking Medicine News(10 mins):Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3
... center, which can go awry , , WEDNESDAY, Jan. 23 ... part of the brain handles what might be called ... lead scientists closer to more effective treatments for a ... brain region is helpful because it provides insight into ...
... fingertips to tap or press a surface is essential ... use a BlackBerry or an iPhone. But researchers ... seemingly trivial action is the result of a complex ... nervous system and muscles of the hand. , ...
... 23, 2008RNA interference (RNAi) represents an innovative new strategy ... associated with disease processes, and a series of review ... RNAi and microRNAs will begin with two review papers ... of Human Gene Therapy, a peer-reviewed journal published by ...
... increased by 18.0% to ... - Medical enrollment grew by 708,000 members during 2007, - Selling, general and ... by 120 basis points during the year, - Operating cash flow exceeded $4.3 billion for the year, or 1.3 ... income, - Company reiterates ...
... KIRKLAND, Wash., Jan. 23 "A failing mind, not ... today," says Cameron,Truesdell, CEO of LTC Financial Partners, the ... be, so we,re going to give,our clients information to ... offering a free guidebook and web links to helpful ...
... for Gestiva(TM) Anticipated in Calendar 2008, Gestiva(TM), is Designated ... Prevention ... in Singleton Pregnancies, ST. LOUIS, Jan. 22 ... company that,develops, manufactures, acquires and markets technology-differentiated,branded and generic/non-branded ...
Cached Medicine News:Health News:Specific Brain Region Governs Problem-Solving Skills 2Health News:Specific Brain Region Governs Problem-Solving Skills 3Health News:What gives us fingertip dexterity? 2Health News:What gives us fingertip dexterity? 3Health News:The RNA drug revolution -- a new approach to gene therapy 2Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 2Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 3Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 4Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 5Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 6Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 7Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 8Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 9Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 10Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 11Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 12Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 13Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 14Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 15Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 16Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 17Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 18Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 19Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 20Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 21Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 22Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 23Health News:Long Term Care Insurance Leader Offers Advice on Preventing Dementia, the Leading Cause of Care Claims 2Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 2Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 3Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 4Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 5
(Date:5/4/2015)... Calif. , May 4, 2015 Rogne ... for psoriasis, today announced that preclinical and mechanism of ... at the Society of Investigative Dermatology (SID) Annual Meeting ... in Atlanta, Georgia . ... advancing the development of RON2315, a novel, low MW ...
(Date:5/4/2015)... WHIPPANY, N.J. , May 4, 2015 ... agreement with Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... clinical development for the prevention of thrombosis. Under the ... in areas of high unmet medical need. As ... evaluate the therapeutic profile of ISIS-FXI Rx in ...
(Date:5/4/2015)... BUFFALO, N.Y. , May 4, 2015 /PRNewswire/ ... Stephanie Englert , PharmD, has completed preliminary analysis ... Disorder and Schizophrenia. Resources from Clinical Support Services, ... Medication Reviews (CMR) with patients currently taking psychiatric ... events. The research found that 93% of patients ...
Breaking Medicine Technology:Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3
... 2, 2012 New Report Added in ... (General, Local, Adjunctive) The World Anesthesia ... , General Anesthesia Local Anesthesia ...   To Browse Full TOC, Tables & Figures visit: ...
... SAN DIEGO, May 2, 2012 Zogenix, Inc. (NASDAQ: ... developing products for the treatment of central nervous system ... submitted a New Drug Application (NDA) to the U.S. ... extended-release capsules), Zogenix,s lead investigational product candidate for the ...
Cached Medicine Technology:ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 2ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 3ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 4ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 5ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 6Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 2Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 3Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 4Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 5Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 6
30 cm - 11 3/4, packages 5 pcs....
23 cm - 9, adult size, for skull thickness up to 12 mm....
Length-9 (229 mm) Tapered retractor blades. 1/16 x 1/4 (1.6 mm x 19 mm)....
Length 6 (152 mm). Greenberg Retractor Kit is supplied with two primary bars. Primary bars attach to skull clamp....
Medicine Products: